| 1. Mai A, Massa S, Pezzi R, Rotili D, Loidl P, Brosch G.. (2003) Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A., 46 (23): [PMID:14584932] [10.1021/jm034167p] |
| 2. Mai A, Massa S, Pezzi R, Simeoni S, Rotili D, Nebbioso A, Scognamiglio A, Altucci L, Loidl P, Brosch G.. (2005) Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides., 48 (9): [PMID:15857140] [10.1021/jm049002a] |
| 3. Smil DV, Manku S, Chantigny YA, Leit S, Wahhab A, Yan TP, Fournel M, Maroun C, Li Z, Lemieux AM, Nicolescu A, Rahil J, Lefebvre S, Panetta A, Besterman JM, Déziel R.. (2009) Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors., 19 (3): [PMID:19111466] [10.1016/j.bmcl.2008.12.045] |
| 4. Estiu G, Greenberg E, Harrison CB, Kwiatkowski NP, Mazitschek R, Bradner JE, Wiest O.. (2008) Structural origin of selectivity in class II-selective histone deacetylase inhibitors., 51 (10): [PMID:18412327] [10.1021/jm7015254] |
| 5. Olsen CA, Ghadiri MR.. (2009) Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides., 52 (23): [PMID:19705846] [10.1021/jm900850t] |
| 6. Estiu G, West N, Mazitschek R, Greenberg E, Bradner JE, Wiest O.. (2010) On the inhibition of histone deacetylase 8., 18 (11): [PMID:20472442] [10.1016/j.bmc.2010.03.080] |
| 7. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R.. (2010) Chemical phylogenetics of histone deacetylases., 6 (3): [PMID:20139990] [10.1038/nchembio.313] |
| 8. Tan DS.. (2005) Diversity-oriented synthesis: exploring the intersections between chemistry and biology., 1 (2): [PMID:16408003] [10.1038/nchembio0705-74] |
| 9. Choi SE, Weerasinghe SV, Pflum MK.. (2011) The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity., 21 (20): [PMID:21889343] [10.1016/j.bmcl.2011.08.027] |
| 10. Feng T, Wang H, Su H, Lu H, Yu L, Zhang X, Sun H, You Q.. (2013) Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2)., 21 (17): [PMID:23820574] [10.1016/j.bmc.2013.06.009] |
| 11. Kalin JH, Bergman JA.. (2013) Development and therapeutic implications of selective histone deacetylase 6 inhibitors., 56 (16): [PMID:23627282] [10.1021/jm4001659] |
| 12. Blackburn C, Barrett C, Chin J, Garcia K, Gigstad K, Gould A, Gutierrez J, Harrison S, Hoar K, Lynch C, Rowland RS, Tsu C, Ringeling J, Xu H.. (2013) Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform., 56 (18): [PMID:23964961] [10.1021/jm400385r] |
| 13. Jones P. (2012) Development of second generation epigenetic agents, 3 (2): [10.1039/C1MD00199J] |
| 14. Blackburn C, Barrett C, Brunson M, Chin J, England D, Garcia K, Gigstad K, Gould A, Gutierrez J, Hoar K, Rowland RS, Tsu C, Ringeling J, Wager K, Xu H.. (2014) Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform., 24 (23): [PMID:25454270] [10.1016/j.bmcl.2014.10.022] |
| 15. Carrillo AK, Guiguemde WA, Guy RK.. (2015) Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT)., 23 (16): [PMID:25637120] [10.1016/j.bmc.2014.12.066] |
| 16. (2016) HDAC inhibitors and therapeutic methods using the same, |
| 17. Lu W, Yao X, Ouyang P, Dong N, Wu D, Jiang X, Wu Z, Zhang C, Xu Z, Tang Y, Zou S, Liu M, Li J, Zeng M, Lin P, Cheng F, Huang J.. (2017) Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis., 60 (5): [PMID:28218840] [10.1021/acs.jmedchem.6b01507] |
| 18. Rabal O, Sánchez-Arias JA, Cuadrado-Tejedor M, de Miguel I, Pérez-González M, García-Barroso C, Ugarte A, Estella-Hermoso de Mendoza A, Sáez E, Espelosin M, Ursua S, Haizhong T, Wei W, Musheng X, Garcia-Osta A, Oyarzabal J.. (2018) Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease., 150 [PMID:29549837] [10.1016/j.ejmech.2018.03.005] |
| 19. Brindisi M, Saraswati AP, Brogi S, Gemma S, Butini S, Campiani G.. (2020) Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases., 63 (1): [PMID:31415174] [10.1021/acs.jmedchem.9b00924] |
| 20. Fleming CL, Natoli A, Schreuders J, Devlin M, Yoganantharajah P, Gibert Y, Leslie KG, New EJ, Ashton TD, Pfeffer FM.. (2019) Highly fluorescent and HDAC6 selective scriptaid analogues., 162 [PMID:30448419] [10.1016/j.ejmech.2018.11.020] |
| 21. Vögerl K, Ong N, Senger J, Herp D, Schmidtkunz K, Marek M, Müller M, Bartel K, Shaik TB, Porter NJ, Robaa D, Christianson DW, Romier C, Sippl W, Jung M, Bracher F.. (2019) Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors., 62 (3): [PMID:30645113] [10.1021/acs.jmedchem.8b01090] |
| 22. Brewitz L,Tumber A,Zhang X,Schofield CJ. (2020) Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase., 28 (20.0): [PMID:33069066] [10.1016/j.bmc.2020.115675] |
| 23. Bao Y,Xu Q,Wang L,Wei Y,Hu B,Wang J,Liu D,Zhao L,Jing Y. (2021) Studying Histone Deacetylase Inhibition and Apoptosis Induction of Psammaplin A Monomers with Modified Thiol Group., 12 (1): [PMID:33488962] [10.1021/acsmedchemlett.0c00369] |
| 24. Mak JYW,Wu KC,Gupta PK,Barbero S,McLaughlin MG,Lucke AJ,Tng J,Lim J,Loh Z,Sweet MJ,Reid RC,Liu L,Fairlie DP. (2021) HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates., 64 (4.0): [PMID:33570940] [10.1021/acs.jmedchem.0c01967] |
| 25. Liang T, Xue J, Yao Z, Ye Y, Yang X, Hou X, Fang H.. (2021) Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors., 221 [PMID:33992929] [10.1016/j.ejmech.2021.113526] |
| 26. Olaoye OO, Watson PR, Nawar N, Geletu M, Sedighi A, Bukhari S, Raouf YS, Manaswiyoungkul P, Erdogan F, Abdeldayem A, Cabral AD, Hassan MM, Toutah K, Shouksmith AE, Gawel JM, Israelian J, Radu TB, Kachhiyapatel N, de Araujo ED, Christianson DW, Gunning PT.. (2021) Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype., 64 (5.0): [PMID:33576627] [10.1021/acs.jmedchem.0c01922] |
| 27. Barone S, Cassese E, Alfano AI, Brindisi M, Summa V.. (2022) Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology., 65 (4.0): [PMID:35148101] [10.1021/acs.jmedchem.1c02067] |
| 28. Li Y, Sang S, Ren W, Pei Y, Bian Y, Chen Y, Sun H.. (2021) Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020)., 226 [PMID:34619465] [10.1016/j.ejmech.2021.113874] |
| 29. Campiani G, Cavella C, Osko JD, Brindisi M, Relitti N, Brogi S, Saraswati AP, Federico S, Chemi G, Maramai S, Carullo G, Jaeger B, Carleo A, Benedetti R, Sarno F, Lamponi S, Rottoli P, Bargagli E, Bertucci C, Tedesco D, Herp D, Senger J, Ruberti G, Saccoccia F, Saponara S, Gorelli B, Valoti M, Kennedy B, Sundaramurthi H, Butini S, Jung M, Roach KM, Altucci L, Bradding P, Christianson DW, Gemma S, Prasse A.. (2021) Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors., 64 (14.0): [PMID:34251197] [10.1021/acs.jmedchem.1c00184] |
| 30. Roche J, Bertrand P.. (2016) Inside HDACs with more selective HDAC inhibitors., 121 [PMID:27318122] [10.1016/j.ejmech.2016.05.047] |
